Improvement of cardiac and systemic function in old mice by agonist of growth hormone‐releasing hormone
- 5 July 2021
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (12) , 8197-8207
Abstract
Age‐related diseases such as cardiovascular diseases portend disability, increase health expenditures, and cause late‐life mortality. Synthetic agonists of growth hormone‐releasing hormone (GHRH) exhibit several favorable effects on heart function and remodeling. Here we assessed whether GHRH agonist MR409 can modulate heart function and systemic parameters in old mice. Starting at the age of 15 months, mice were injected subcutaneously with MR409 (10 µg/day, n = 8) or vehicle (n = 7) daily for 6 months. Mice treated with MR409 showed improvements in exercise activity, cardiac function, survival rate, immune function, and hair growth in comparison with the controls. More stem cell colonies were grown out of the bone marrow recovered from the MR409‐treated mice. Mitochondrial functions of cardiomyocytes (CMs) from the MR409‐treated mice were also significantly improved with more mitochondrial fusion. Fewer β‐gal positive cells were observed in endothelial cells after 10 passages with MR409. In Doxorubicin‐treated H9C2 cardiomyocytes, cell senescence marker p21 and reactive oxygen species were significantly reduced after cultured with MR409. MR409 also improved cellular ATP production and oxygen consumption rate in Doxorubicin‐treated H9C2 cells. Mitochondrial protein OPA1 long isoform was significantly increased after treatment with MR409. The effects of MR409 were mediated by GHRH receptor and protein kinase A (PKA). In short, GHRH agonist MR409 reversed the aging‐associated changes with respect of heart function, mobility, hair growth, cellular energy production, and senescence biomarkers. The improvement of heart function may be related to a better mitochondrial functions through GHRH receptor/cAMP/PKA/OPA1 signaling pathway and relieved cardiac inflammation.Keywords
Funding Information
- National Natural Science Foundation of China (81570251, 82070448)
This publication has 42 references indexed in Scilit:
- The Hallmarks of AgingCell, 2013
- Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edemaProceedings of the National Academy of Sciences, 2012
- Cardiomyocyte deletion of mitofusin-1 leads to mitochondrial fragmentation and improves tolerance to ROS-induced mitochondrial dysfunction and cell deathAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)Proceedings of the National Academy of Sciences, 2011
- Multi-Analyte Profiling Reveals Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 as Plasma Biomarkers of Cardiac AgingCirculation: Cardiovascular Genetics, 2011
- Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarctionProceedings of the National Academy of Sciences, 2010
- Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1Journal of Cell Biology, 2009
- Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cellsJournal of Cell Biology, 2009
- Mitochondrial OPA1, apoptosis, and heart failureCardiovascular Research, 2009
- OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1LJournal of Cell Biology, 2007